Horizon Discovery has entered into a non-exclusive license agreement with ERS Genomics, Ltd. to access intellectual property for the CRISPR/Cas9 gene editing system. Access to the CRISPR IP portfolio will allow the technology to be deployed extensively across Horizon’s products, services and leveraged R&D.
Horizon gains rights to use the technology for research applications including: development and sale of research tools, kits and reagents, performance of research services, creation of genetically modified disease model cell lines, development and production of reference standard material for molecular diagnostics, and for internal target identification and validation research efforts.
“Horizon Discovery’s ambition is to be the market leader in CRISPR technology, and by expanding our portfolio of intellectual property rights in this area we aim to ensure that our customers, both now and in the future, will have unencumbered access to this innovative new gene editing technology,” said Dr. Darrin Disley, chief executive officer of Horizon Discovery Group. “We believe that the ERS Genomics IP, based on the work of Dr. Emmanuelle Charpentier and her colleagues, is particularly important and so we are very pleased to be able to add it to our expanding portfolio of patent rights in this area on behalf of our customers.”